Capecitabine Market Growth Analysis, New Opportunities And Forecast 2024-2033

The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.

Capecitabine Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.

The Market Size Is Expected To Reach $3.14 billion In 2028 At A CAGR Of 8.7%.

The capecitabine market size has grown strongly in recent years. It will grow from $2.06 billion in 2023 to $2.25 billion in 2024 at a compound annual growth rate (CAGR) of 9.4%. The growth in the historic period can be attributed to chemotherapy advancements, convenience of oral administration, regulatory approvals, treatment accessibility, oncologist recommendations.

The capecitabine market size is expected to see strong growth in the next few years. It will grow to $3.14 billion in 2028 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to expanded indications, research in combination therapies, healthcare infrastructure development, government initiatives, adoption in developing countries. Major trends in the forecast period include targeted therapy combinations, expanded use in adjuvant settings, biomarker-driven treatment, enhanced pharmacogenomics, telehealth monitoring.

Request A Sample Of This Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=12240&type=smp

Capecitabine Market Major Segments
The capecitabine market covered in this report is segmented -
1) By Drug Type: Branded, Generic
2) By Drug Formulation: Tablet, Capsules
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) By Application: Colon Cancer, Rectal Cancer, Breast Cancer, Gastric Cancer, Other Applications
5) By End-Users: Hospitals, Homecare, Specialty Centers, Other End-Users

Key Driver - Rising Cancer Incidence Fuels Growth In The Capecitabine Market

The increasing incidence of cancer is expected to propel the growth of the capecitabine market going forward. Cancer is a broad category of illnesses that can develop in any organ or tissue in the body when aberrant cells proliferate uncontrollably, cross their usual boundaries, and either spread to other organs or invade neighboring body parts. Capecitabine is used as a chemotherapeutic medication in cancer treatment, where it is enzymatically converted into the antimetabolite fluorouracil in the tumor, inhibiting DNA synthesis and slowing tumor tissue growth. For instance, in 2021, according to the American Cancer Society, a US-based community-based, voluntary health organization, there were an estimated 1.9 million new cancer cases diagnosed and 608,570 cancer deaths in the United States in 2021, an increase from 1.8 million new cancer cases diagnosed and 606,520 cancer deaths reported in 2020. Therefore, the increasing incidence of cancer is driving the growth of the capecitabine market.

Customise This Report As Per Your Requirements -
https://www.thebusinessresearchcompany.com/Customise?id=12240&type=smp

Prominent Trend - Generic Tablets For Cost-Effective Cancer Treatment

Product innovations are a key trend gaining popularity in the behavioral rehabilitation market. Major companies in the capecitabine market are focused on developing generic tablets to drive their revenues in the market. For instance, in February 2021, Dr. Reddy's Laboratories, an India-based pharmaceutical company, launched Capecitabine tablets, a generic version of Xeloda, in the U.S. market. The therapeutic equivalent drug, approved by the U.S. Food and Drug Administration, is used in cancer treatment. The tablets are available in 150 mg and 500 mg strengths, in bottle counts of 60 and 120, respectively.

Capecitabine Market Players
Major companies operating in the capecitabine market report are Pfizer Inc., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Sensus Healthcare Inc., Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Inc., Genentech Inc., Aurobindo Pharma Limited, Dr Reddy Laboratories Ltd., Sigma-Aldrich Corp, Cipla Inc., Hikma Pharmaceuticals plc, Lupin Limited, Alkem Laboratories Limited, Ranbaxy Laboratories Ltd., Glenmark Pharmaceuticals Ltd., Accord Healthcare Ltd., Zentiva N.V., Reliance Life Sciences Pvt Ltd., Avita Medical Limited, Mylan Inc., Sandoz Inc.

View The Full Report Here -
https://www.thebusinessresearchcompany.com/report/capecitabine-global-market-report

Largest And Fastest Growing Region In The Market
North America was the largest region in the capecitabine market in 2023. The regions covered in the capecitabine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Capecitabine Market Report Structure
3. Capecitabine Market Trends And Strategies
4. Capecitabine Market - Macro Economic Scenario
5. Capecitabine Market Size And Growth
…..
27. Capecitabine Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.